RESUMEN
Post-laparoscopic pain is multi-factorial and many modes of perioperative analgesia have been proposed. We present the case of a patient who experienced severe abdominal pain following gynaecologic laparoscopy. Repeat laparoscopy revealed small bowel hypermotiliy which was successfully treated with intravenous (i.v.) hyoscine butylbromide. Neostigmine, a widely used muscle relaxant reversal agent, is known to increase small bowel motility. Intravenous hyoscine butylbromide is a rapid treatment of neostigmine-induced small bowel hypermotility post-laparoscopy.
Asunto(s)
Bromuro de Butilescopolamonio/uso terapéutico , Motilidad Gastrointestinal/efectos de los fármacos , Laparoscopía/efectos adversos , Parasimpatolíticos/uso terapéutico , Parasimpaticomiméticos/efectos adversos , Dolor Abdominal/etiología , Femenino , Humanos , Neostigmina/efectos adversos , Adulto JovenRESUMEN
BACKGROUND: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. OBJECTIVE: The goal of this study was to determine whether initiation of warfarin treatment in patients with AF, while in thc hospital, is associated with an increased length of stay. METHODS: This was a prospective audit involving patients with AF newly started on warfarin while in the hospital. It was conducted in 3 acute medical wards (total, 96 beds) of a district general hospital. Patients were reviewed daily regarding the necessity of their hospital stay. Their stay was considered delayed if their original medical condition had resolved and their stay was attributed solely to initiation of warfarin to reach a therapeutic International Normalized Ratio (INR). The Barthel Index score was used to assess patients' activities of daily living. The medical teams treating these patients were unaware of the objective of the study. RESULTS: Over a 6-month period, 23 patients with AF (13 men, 10 women; mean [SD] age, 75.4 [9.2] years) were started on warfarin while in the hospital and thus comprised our study group. Of these 23 patients, 7 (30%) had delayed discharges that were solely attributed to initiation of warfarin. Total length of stay for all patients combined was 217 days; of these, 36 (17%) days were considered delayed discharges. Only 10 (43%) patients were discharged with their INR in the target range of 2 to 3. There was no significant difference between patients who had delayed discharges versus nondelayed discharges in terms of age, sex, number of comorbidities, number of medications, Barthel Index score, reason for admission, mean INR, number of patients achieving target INR on discharge, or main warfarin loading regimens. CONCLUSIONS: Initiation of warfarin in these patients with AF while in the hospital led to increased length of stay. A move toward starting anticoagulation in an outpatient setting could reduce length of hospital stay.
Asunto(s)
Anticoagulantes/administración & dosificación , Fibrilación Atrial/tratamiento farmacológico , Tiempo de Internación , Warfarina/administración & dosificación , Actividades Cotidianas , Anciano , Anciano de 80 o más Años , Femenino , Hospitales de Distrito , Hospitales Generales , Humanos , Relación Normalizada Internacional , Masculino , Auditoría Médica , Persona de Mediana Edad , Estudios ProspectivosRESUMEN
Gynecologic cancers are major sources of mortality and morbidity. Although many review articles have reported on the impact of these diseases on health-related quality of life (HRQoL), none have reviewed the evidence in specific relation to the effect of treatment on HRQoL. Consequently, we systematically searched 4 electronic databases and hand-searched relevant reference lists and bibliographies to identify literature on this subject. Only 47 studies used a validated questionnaire to measure HRQoL. Although a meta-analysis was not possible, we found HRQoL rarely included as a treatment outcome, and when included assessment was often methodologically flawed. Seldom were pretreatment and posttreatment data collected or treatment regimes documented. Except for a few studies, analysis of HRQoL was conducted on small samples, excluding the cancer site and stage. Consequently, no definitive conclusions could be drawn and therefore we conclude with recommendations for the future reporting of HRQoL in gynecologic oncology studies.